Status:
COMPLETED
Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches
Lead Sponsor:
Yale University
Conditions:
Refractory Migraine
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The hypothesis of this study is that injection of botulinum toxin A into the muscles around the head (frontal, temporal, posterior neck, occipital) can reduce the intensity and frequency of migraine h...
Detailed Description
Contact PI for study details
Eligibility Criteria
Inclusion
- Adults 18 and older
- Migraine for more than three months, that fail to respond to two or more major anti-migraine drug, meeting criteria of chronic migraine
Exclusion
- Age below 18
- Pregnant or may become pregnant
- Disease of neuromuscular junction or drugs that affect N-M junction
- Allergy to Botox
- Previous use of Botox for migraine by similar methodology
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2015
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00660192
Start Date
January 1 2008
End Date
July 1 2015
Last Update
March 14 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale Physician's Building, 800 Howard Ave, lower level,
New Haven, Connecticut, United States, 06510